Twist Bioscience Corporation reported $432M of revenue over the trailing twelve months, +19% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $432M (to Q3 2026). Net income: −$137M, trailing twelve months to Q3 2026. Free cash flow: −$93M, trailing twelve months to Q3 2026. Operating margin: −34%, trailing twelve months to Q3 2026.

TWSTTwist Bioscience Corporation

Healthcare

$159.83+473% 1Y

$159.83

$25.4552 weeks$204.94

TWST as reported

Twist Bioscience Corporation reported $432M of revenue over the trailing twelve months, +19% on the year before. 10 reported series are charted on this page, each one as filed.

$432M

Revenue, trailing twelve months · to Q3 2026 · +19% against the twelve months before

Net income: −$137M
Net income · +60% year on year · trailing twelve months to Q3 2026
Free cash flow: −$93M
Free cash flow · +36% year on year · trailing twelve months to Q3 2026
Operating margin: −34%
Operating margin · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for TWST, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$432M	+19%	Q3 2026
Net income	−$137M	+60%	Q3 2026
EPS	−$2.22	+53%	Q3 2026
Gross margin	52%	n/a	Q3 2026
Operating margin	−34%	n/a	Q3 2026
Net margin	−32%	n/a	Q3 2026
ROE	−20%	n/a	Q3 2026
ROA	−14%	n/a	Q3 2026
ROIC	−139%	n/a	Q4 2021 · 19 quarters behind
Free cash flow	−$93M	+36%	Q3 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.